7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $31M | -$74M | 0.0% | -279.5% | 68.5% | -37.5% | -$86M | — | $81M |
| 2024 | $23M | -$87M | 0.0% | -454.3% | 190.3% | -30.5% | -$101M | — | $55M |
| 2023 | $34M | -$98M | 0.0% | -315.9% | 127.5% | -34.4% | -$119M | — | $80M |
| 2022 | $19M | -$109M | 0.0% | -609.2% | -97216.1% | -26.9% | $192M | — | $52M |
| 2021 | $1M | -$101M | 0.0% | -7637.1% | -104.6% | -19.5% | -$54M | $0 | $101M |
| 2020 | $430000 | -$69M | 0.0% | -15937.4% | -47.1% | -26.9% | -$47M | $20M | $93M |
| 2019 | — | -$51M | — | — | 58.1% | -228.8% | -$47M | $15M | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $16M | -$7M | 0.0% | -54.8% | 8.9% | -3.5% | -$18M | — | $68M |
| Mar '26 | $3M | -$20M | 0.0% | -660.3% | 26.0% | -8.9% | -$25M | — | $88M |
| Dec '25 | $9M | -$22M | 0.0% | -258.2% | 20.0% | -10.9% | -$22M | — | $81M |
| Sep '25 | $8M | -$16M | 0.0% | -226.9% | 17.7% | -7.7% | -$19M | — | $89M |
| Jun '25 | $8M | -$18M | 0.0% | -279.2% | 23.4% | -7.9% | -$21M | — | $73M |
| Mar '25 | $6M | -$19M | 0.0% | -385.0% | 30.5% | -7.3% | -$24M | — | $61M |
| Dec '24 | $3M | -$20M | 0.0% | -840.5% | 42.8% | -6.9% | -$25M | — | $55M |
| Sep '24 | $8M | -$19M | 0.0% | -305.5% | 67.6% | -6.2% | -$21M | — | $58M |
| Jun '24 | $7M | -$23M | 0.0% | -386.6% | 160.4% | -7.0% | -$26M | — | $139M |
| Mar '24 | $5M | -$25M | 0.0% | -558.3% | 25.7% | -9.8% | -$29M | — | $79M |
| Dec '23 | $6M | -$24M | 0.0% | -441.3% | 31.2% | -8.4% | -$28M | — | $80M |
| Sep '23 | $17M | -$14M | 0.0% | -97.7% | 25.0% | -4.6% | -$27M | — | $70M |
| Jun '23 | $6M | -$29M | 0.0% | -572.4% | 59.8% | -8.7% | -$33M | — | $58M |
| Mar '23 | $5M | -$30M | 0.0% | -627.6% | 124.0% | -8.2% | -$32M | — | $51M |
| Dec '22 | $4M | -$29M | 0.0% | -762.1% | -25791.1% | -7.1% | -$29M | — | $52M |
| Sep '22 | $7M | -$26M | 0.0% | -426.0% | -105.9% | -5.9% | -$20M | — | $88M |
| Jun '22 | $4M | -$27M | 0.0% | -650.1% | -57.3% | -6.0% | -$29M | — | $61M |
| Mar '22 | $4M | -$27M | 0.0% | -709.3% | -37.2% | -5.5% | $271M | — | $214M |
| Dec '21 | $713000 | -$29M | 0.0% | -3938.6% | -30.1% | -5.6% | $12M | $0 | $101M |
| Sep '21 | $41000 | -$26M | 0.0% | -64051.2% | -32.2% | -14.0% | -$21M | $20M | $58M |
How the market has priced FHTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Foghorn Therapeutics Inc.'s revenue has grown 135.1% per year. These are computed facts, not advice.
As of FY2025, Foghorn Therapeutics Inc. reported — of total debt against $81M of cash.
In FY2025, gross margin was —, operating margin -279.5%, and net margin -240.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.